How Cell and Gene Manufacturers Can Scale to Meet Demand
Between 2022 and 2030, the cell and gene therapy sector is expected to experience a compound annual growth rate (CAGR) of 39.42 percent, BioSpace said of a recent Vision Research Report. This is quite a large anticipated growth; how will startups and current manufacturing companies work to meet this growing demand? On today’s episode of…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Promoted content from Benchmark Products on MarketScale.
Free workspace
Turn your Healthcare expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
Between 2022 and 2030, the cell and gene therapy sector is expected to experience a compound annual growth rate (CAGR) of 39.42 percent, BioSpace said of a recent Vision Research Report.
This is quite a large anticipated growth; how will startups and current manufacturing companies work to meet this growing demand?
On today’s episode of Exceeding Your Benchmark, Host Sumit Verma, Senior Vice President, Global Strategic Manufacturing at Iovance Biotherapeutics, addresses cell and gene therapy industry trends and challenges and what manufacturers can do to promote growth in the sector.
Verma also discussed…
- The greatest challenges biopharma startups face
- How established CGT manufacturers are preparing to meet an increased demand
- What place automation has in advanced cell manufacturing
Verma believes there are three key areas manufacturers need to target to help supply meet increasing demand. “I think most players are focusing on three big things: one is around scalability, the second is around supply chain, making sure we have all the components, and last is about talent. Verma said of the talent piece, “There aren’t many people who have advanced programs for therapeutic manufacturing today…there are a lot of synergies and the big pharma have done a great job establishing developing programs that are very supportive of their large plants and their scalable efforts and we’ve seen the need to do that in cell and gene therapy.
Part of this channel
Benchmark Products
ISO-certified cleanroom supplies for life science manufacturers.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
